JP7383023B2 - プロバイオティクス菌株と多価不飽和脂肪酸成分とを含む調製物 - Google Patents
プロバイオティクス菌株と多価不飽和脂肪酸成分とを含む調製物 Download PDFInfo
- Publication number
- JP7383023B2 JP7383023B2 JP2021529679A JP2021529679A JP7383023B2 JP 7383023 B2 JP7383023 B2 JP 7383023B2 JP 2021529679 A JP2021529679 A JP 2021529679A JP 2021529679 A JP2021529679 A JP 2021529679A JP 7383023 B2 JP7383023 B2 JP 7383023B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid
- health
- bacillus megaterium
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 39
- 239000006041 probiotic Substances 0.000 title claims description 21
- 235000018291 probiotics Nutrition 0.000 title claims description 21
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title claims description 18
- 230000000529 probiotic effect Effects 0.000 title claims description 15
- 241000194107 Bacillus megaterium Species 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 40
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 39
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 33
- 108091033319 polynucleotide Proteins 0.000 claims description 29
- 102000040430 polynucleotide Human genes 0.000 claims description 29
- 239000002157 polynucleotide Substances 0.000 claims description 29
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 27
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 27
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 27
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 27
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 26
- 239000006185 dispersion Substances 0.000 claims description 24
- 230000036541 health Effects 0.000 claims description 20
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 18
- -1 fish oils Chemical class 0.000 claims description 18
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 17
- 239000006014 omega-3 oil Substances 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 16
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 15
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 15
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 150000003904 phospholipids Chemical class 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 235000015872 dietary supplement Nutrition 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 235000021342 arachidonic acid Nutrition 0.000 claims description 9
- 229940114079 arachidonic acid Drugs 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 7
- 101100321034 Bacillus subtilis (strain 168) yqfD gene Proteins 0.000 claims description 7
- 101100439426 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) groEL4 gene Proteins 0.000 claims description 7
- 101100267109 Escherichia coli (strain K12) ygfF gene Proteins 0.000 claims description 7
- 125000004494 ethyl ester group Chemical group 0.000 claims description 7
- 101150077981 groEL gene Proteins 0.000 claims description 7
- 101150013736 gyrB gene Proteins 0.000 claims description 7
- 101150012629 parE gene Proteins 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 235000013406 prebiotics Nutrition 0.000 claims description 5
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 4
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 4
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 4
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 4
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 230000010035 cardiometabolic health Effects 0.000 claims description 3
- 230000036996 cardiovascular health Effects 0.000 claims description 3
- 230000000112 colonic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940013317 fish oils Drugs 0.000 claims description 3
- 235000012041 food component Nutrition 0.000 claims description 3
- 239000005417 food ingredient Substances 0.000 claims description 3
- 235000021588 free fatty acids Nutrition 0.000 claims description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 3
- 229960002733 gamolenic acid Drugs 0.000 claims description 3
- 230000007413 intestinal health Effects 0.000 claims description 3
- 230000037231 joint health Effects 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- 230000004630 mental health Effects 0.000 claims description 3
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 2
- 238000013452 biotechnological production Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 235000013384 milk substitute Nutrition 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940124536 anticoccidial agent Drugs 0.000 claims 1
- 239000003224 coccidiostatic agent Substances 0.000 claims 1
- 230000003862 health status Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 36
- IVVBLUGHDNNLFF-UHFFFAOYSA-N 18-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCC(O)CCCCCCC=CC=CC=CC=CC=CC(O)=O IVVBLUGHDNNLFF-UHFFFAOYSA-N 0.000 description 30
- 238000009472 formulation Methods 0.000 description 19
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 244000005700 microbiome Species 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 11
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- CRDZYJSQHCXHEG-SFVBTVKNSA-N protectin D1 Chemical compound CC\C=C/C[C@H](O)\C=C/C=C/C=C/[C@H](O)C\C=C/C\C=C/CCC(O)=O CRDZYJSQHCXHEG-SFVBTVKNSA-N 0.000 description 8
- SWTYBBUBEPPYCX-VIIQGJSXSA-N (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O SWTYBBUBEPPYCX-VIIQGJSXSA-N 0.000 description 7
- HLHYXXBCQOUTGK-FHCQLJOMSA-N (7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C[C@H](O)\C=C/C=C/C=C/[C@H](O)C\C=C/CCC(O)=O HLHYXXBCQOUTGK-FHCQLJOMSA-N 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- AOPOCGPBAIARAV-OTBJXLELSA-N resolvin E1 Chemical compound CC[C@@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O AOPOCGPBAIARAV-OTBJXLELSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 6
- 101100038261 Methanococcus vannielii (strain ATCC 35089 / DSM 1224 / JCM 13029 / OCM 148 / SB) rpo2C gene Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000021323 fish oil Nutrition 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 238000006213 oxygenation reaction Methods 0.000 description 6
- 101150085857 rpo2 gene Proteins 0.000 description 6
- 101150090202 rpoB gene Proteins 0.000 description 6
- FTAGQROYQYQRHF-FCWZHQICSA-N 5-HEPE Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C=C/C(O)CCCC(O)=O FTAGQROYQYQRHF-FCWZHQICSA-N 0.000 description 5
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 5
- KGIJOOYOSFUGPC-XRXZHELTSA-N 5-hydroxyeicosatetraenoic acid Natural products CCCCCC=CCC=CCC=C\C=C\C(O)CCCC(O)=O KGIJOOYOSFUGPC-XRXZHELTSA-N 0.000 description 5
- KROOJMCNWRRPCC-UHFFFAOYSA-N 8-hydroxyeicosatetraenoic acid Natural products CCCCCC=CCC=CCC=C(O)CC=CCCCC(O)=O KROOJMCNWRRPCC-UHFFFAOYSA-N 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 description 5
- 229920001046 Nanocellulose Polymers 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 102000004020 Oxygenases Human genes 0.000 description 5
- 108090000417 Oxygenases Proteins 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- WYCMUVNNXSREQB-AZOGICFMSA-N resolvin E3 Chemical compound CC[C@H](O)C(O)\C=C\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WYCMUVNNXSREQB-AZOGICFMSA-N 0.000 description 5
- ALWYOLKNLLFCAY-GYROAIJESA-N (13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C[C@H](O)[C@H](O)\C=C\C=C\C=C/C\C=C/CCC(O)=O ALWYOLKNLLFCAY-GYROAIJESA-N 0.000 description 4
- MCRJLMXYVFDXLS-QGQBRVLBSA-N 12-HEPE Chemical compound CC\C=C/C\C=C/CC(O)\C=C\C=C/C\C=C/CCCC(O)=O MCRJLMXYVFDXLS-QGQBRVLBSA-N 0.000 description 4
- 150000000668 8-HETE derivatives Chemical class 0.000 description 4
- 108010052832 Cytochromes Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229960003104 ornithine Drugs 0.000 description 4
- GCZRCCHPLVMMJE-JVNZAOJVSA-N (5e,8e,12e,14e)-11-hydroxyicosa-5,8,12,14-tetraenoic acid Chemical compound CCCCC\C=C\C=C\C(O)C\C=C\C\C=C\CCCC(O)=O GCZRCCHPLVMMJE-JVNZAOJVSA-N 0.000 description 3
- GPQVVJQEBXAKBJ-JPURVOHMSA-N 17(18)-EpETE Chemical compound CCC1OC1C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O GPQVVJQEBXAKBJ-JPURVOHMSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- IXAQOQZEOGMIQS-ORRYEOPJSA-N Lipoxin A Natural products CCCCCC(O)C=CC=C/C=C/C=C/C(O)C(O)CCCC(=O)O IXAQOQZEOGMIQS-ORRYEOPJSA-N 0.000 description 3
- 102000003820 Lipoxygenases Human genes 0.000 description 3
- 108090000128 Lipoxygenases Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229960004232 linoleic acid Drugs 0.000 description 3
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000004668 long chain fatty acids Chemical group 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000006225 natural substrate Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- IKFAUGXNBOBQDM-XFMPMKITSA-N resolvin D2 Chemical compound CC\C=C/C[C@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)C\C=C/CCC(O)=O IKFAUGXNBOBQDM-XFMPMKITSA-N 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019722 synbiotics Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UXVRTOKOJOMENI-ICTGYCPSSA-N (6e,8e,10e,12e)-5,14,15-trihydroxyicosa-6,8,10,12-tetraenoic acid Chemical compound CCCCCC(O)C(O)\C=C\C=C\C=C\C=C\C(O)CCCC(O)=O UXVRTOKOJOMENI-ICTGYCPSSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HNICUWMFWZBIFP-IRQZEAMPSA-N 13(S)-HODE Chemical compound CCCCC[C@H](O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-IRQZEAMPSA-N 0.000 description 2
- OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 description 2
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000504943 Bacillus megaterium NBRC 15308 = ATCC 14581 Species 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920003043 Cellulose fiber Polymers 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 244000008991 Curcuma longa Species 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 101000935569 Homo sapiens Zinc finger protein basonuclin-1 Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 102100027904 Zinc finger protein basonuclin-1 Human genes 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- CRDZYJSQHCXHEG-HBMALMRFSA-N aspirin-triggered protectin D1 Chemical compound CC\C=C/C[C@@H](O)\C=C/C=C/C=C/[C@H](O)C\C=C/C\C=C/CCC(O)=O CRDZYJSQHCXHEG-HBMALMRFSA-N 0.000 description 2
- OIWTWACQMDFHJG-BJEBZIPWSA-N aspirin-triggered resolvin D1 Chemical compound CC\C=C/C[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)C\C=C/CCC(O)=O OIWTWACQMDFHJG-BJEBZIPWSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 239000002121 nanofiber Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- OIWTWACQMDFHJG-CCFUIAGSSA-N resolvin D1 Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)C\C=C/CCC(O)=O OIWTWACQMDFHJG-CCFUIAGSSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- RGBUEIHKUZWFQU-UHFFFAOYSA-N 11-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound OC(=CC=CC=CC=CC=CC(=O)O)CCCCCCCCC RGBUEIHKUZWFQU-UHFFFAOYSA-N 0.000 description 1
- ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- IQMBFVPVALDBIC-UHFFFAOYSA-N 8-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCC=CC=C(O)C=CC=CC=CC(O)=O IQMBFVPVALDBIC-UHFFFAOYSA-N 0.000 description 1
- LIBBWEZNMNXORM-UHFFFAOYSA-N 8-hydroxyicosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCC=C(O)C=CC=CC=CC(O)=O LIBBWEZNMNXORM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- CUHJQOVOXFVMSQ-UHFFFAOYSA-N 9-hydroxyoctadeca-2,4-dienoic acid Chemical compound CCCCCCCCCC(O)CCCC=CC=CC(O)=O CUHJQOVOXFVMSQ-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229920002749 Bacterial cellulose Polymers 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
- 101001064864 Homo sapiens Polyunsaturated fatty acid lipoxygenase ALOX12 Proteins 0.000 description 1
- 101001064853 Homo sapiens Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000005298 Iron-Sulfur Proteins Human genes 0.000 description 1
- 108010081409 Iron-Sulfur Proteins Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 1
- 102100031949 Polyunsaturated fatty acid lipoxygenase ALOX12 Human genes 0.000 description 1
- 102100031950 Polyunsaturated fatty acid lipoxygenase ALOX15 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101000877889 Pseudomonas putida Flavin reductase Proteins 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001165 anti-coccidial effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 239000005016 bacterial cellulose Substances 0.000 description 1
- 229940098396 barley grain Drugs 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940106265 charcoal Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- ATNNLHXCRAAGJS-UHFFFAOYSA-N docos-2-enoic acid Chemical class CCCCCCCCCCCCCCCCCCCC=CC(O)=O ATNNLHXCRAAGJS-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940050549 fiber Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229940005741 sunflower lecithin Drugs 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/187—Eicosapentaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1872—Linoleic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1874—Linolenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1882—Polyunsaturated fatty acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
a)DSMZにおいてDSM 32963、DSM 33296、およびDSM 33299において寄託されたバチルス・メガテリウム株のうちの1つ、
b)DSM 32963株の全ての特定された特徴を有する、DSM 32963にて寄託されたバチルス・メガテリウム株の変異体であって、好ましくは、DSM 32963に対して少なくとも95%、好ましくは少なくとも96%、97%、または98%、より好ましくは少なくとも99%または99.5%のDNA配列同一性を有する、変異体、
c)(a)または(b)の調製物、
d)(a)、(b)、または(c)に含まれるような代謝物質による有効な混合物を含有する調製物、
から選択される。
a)配列番号1または配列番号2によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有する16S rDNA配列、
b)配列番号3によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するyqfD配列、
c)配列番号4によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgyrB配列、
d)配列番号5によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するrpoB配列、
e)配列番号6によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgroEL配列
を示す。
a)配列番号13または配列番号14によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有する16S rDNA配列、
b)配列番号15によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するyqfD配列、
c)配列番号16によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgyrB配列、
d)配列番号17によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するrpoB配列、
e)配列番号18によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgroEL配列
を示す。
a)配列番号25または配列番号26によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有する16S rDNA配列、
b)配列番号27によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するyqfD配列、
c)配列番号28によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgyrB配列、
d)配列番号29によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するrpoB配列、
e)配列番号30によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgroEL配列
を示す。
a)配列番号1または配列番号2、配列番号13または配列番号14、あるいは配列番号25または配列番号26によるポリヌクレオチド配列に対して少なくとも99%、好ましくは少なくとも99.5%、より好ましくは少なくとも99.8、または99.9%、とりわけ100%の配列同一性を有する16S rDNA配列、
b)配列番号3、配列番号15、または配列番号27によるポリヌクレオチド配列に対して少なくとも99.5%、より好ましくは少なくとも99.8%または99.9%、とりわけ100%の配列同一性を有するyqfD配列、
c)配列番号4、配列番号16、または配列番号28によるポリヌクレオチド配列に対して少なくとも99%、好ましくは少なくとも99.5%、より好ましくは少なくとも99.8または99.9%、とりわけ100%の配列同一性を有するgyrB配列、
の少なくとも1つ、好ましくは全てを示すバチルス・メガテリウム株、特に上記において言及したバチルス・メガテリウム株である。
d)配列番号5、配列番号17、または配列番号29によるポリヌクレオチド配列に対して少なくとも99%、好ましくは少なくとも99.5%、より好ましくは少なくとも99.8または99.9%、とりわけ100%の配列同一性を有するrpoB配列、
e)配列番号6、配列番号18、または配列番号30によるポリヌクレオチド配列に対して少なくとも99%、好ましくは少なくとも99.5%、より好ましくは少なくとも99.8または99.9%、とりわけ100%、の配列同一性を有するgroEL配列
のうちの少なくとも1つ、より好ましくは全てを示す。
a)配列番号1または配列番号2、配列番号13または配列番号14、あるいは配列番号25または配列番号26による16S rDNA配列、
b)配列番号3、配列番号15、または配列番号27によるyqfD配列、
c)配列番号4、配列番号16、または配列番号28によるgyrB配列
を示すバチルス・メガテリウム株でもある。
d)配列番号5、配列番号17、または配列番号29によるrpoB配列、
e)配列番号6、配列番号18、または配列番号30によるgroEL配列
を示す。
-胃腸内微生物による産生によって、宿主における以下の脂質メディエータの総量を増加させること:
17-ヒドロキシ-DHA(17-HDHA)、14-ヒドロキシ-DHA(14-HDHA)、13-ヒドロキシ-DHA(13-HDHA)、7-ヒドロキシ-DHA(7-HDHA)、4-ヒドロキシ-DHA(4-HDHA)、18-ヒドロキシ-エイコサペンタエン酸(18-HEPE)、15-ヒドロキシ-エイコサペンタエン酸(15-HEPE)、12-ヒドロキシ-エイコサペンタエン酸(12-HEPE)、11-ヒドロキシ-エイコサペンタエン酸(11-HEPE)、8-ヒドロキシ-エイコサペンタエン酸(8-HEPE)、5-ヒドロキシ-エイコサペンタエン酸(5-HEPE)、15-ヒドロキシ-エイコサテトラエン酸(15-HETE)、12-ヒドロキシ-エイコサテトラエン酸(12-HETE)、11-ヒドロキシ-エイコサテトラエン酸(11-HETE)、8-ヒドロキシ-エイコサテトラエン酸(8-HETE)、5-ヒドロキシ-エイコサテトラエン酸(5-HETE)、9-ヒドロキシオクタデカジエン酸(9-HODE)、13-ヒドロキシオクタデカジエン酸(13-HODE)、19Z-ドコサヘキサエン酸(PDX)、プロテクチンD1(PD1)、アスピリンが原因のPD1(AT-PD1)、マレシン1(MaR1)、マレシン2(MaR2)、ロイコトリエンB4(LTB4)、t-LTB4、レゾルビンD1-5(RvD1-5)、アスピリンが原因のRvD1(AT-RvD1)、レゾルビンE1(RvE1)、レゾルビンE3(RvE3)、リポキシンA4(LXA4)、リポキシンA5(LXA5)、リポキシンB4(LXB4)、リポキシンB5(LXB5)、
-宿主におけるEPAの総量を増加させること、
-宿主におけるDHAの総量を増加させること、
の1つまたは複数によって、動物または人間の健康状態を改善するための組成物である。
-セルロース繊維またはナノウィスカの網目構造を含むBNC、
-セルロース繊維の2つ以上の異なる層を含むBNCであって、各層が、異なる微生物または異なる条件下において培養された微生物由来のBNCからなる、BNC、
-少なくとも2つの異なるセルロース網目構造で構成されるBNC、または、
-ポリマーをさらに含むBNC複合材料
から選択される、細菌によって合成されたナノセルロース(BNC)である。
a)配列番号1または配列番号2、配列番号13または配列番号14、配列番号25または配列番号26によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有する16S rDNA配列、および/または、
b)配列番号3、配列番号15、または配列番号27によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するyqfD配列、および/または、
c)配列番号4、配列番号16、配列番号28によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgyrB配列、および/または、
d)配列番号5、配列番号17、配列番号29によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するrpoB配列、および/または、
e)配列番号6、配列番号18、配列番号30によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgroEL配列
を示す、休眠形態の、または栄養細胞としての、バチルス・メガテリウム株の使用でもある
実施例1:バチルス・メガテリウム株DSM 32963、DSM 33296、およびDSM 33299のそれぞれは、チトクロームP450モノオキシゲナーゼ(CYP450)のための遺伝子配列を有する
バチルス・メガテリウム株DSM 32963、DSM 33296、およびDSM 33299を、それぞれ、東ウェストファリアにおける本来のままの庭の土壌試料から単離した。それらは、Evonik Degussa GmbHの名において、上記において言及したような受託番号により、Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedureの規定の下、2018年11月27日(DSM 32963)および2019年10月17日に、DSMZに寄託されている。
ω3脂肪酸調製物の配合物を調製するため、0.8gのジオレイルホスファチジルコリン(DOPC、Lipoid GmbH)を1mlのエタノールに溶解させた。0.2gの魚油(Omega-3 1400、Doppelherz(登録商標))、ω3エチルエステル(PronovaPure(登録商標) 500:200 EE、BASF)またはω3リジン塩の形態の遊離ω3脂肪酸のリジン塩(AvailOm(登録商標)、Evonik)を加えて溶解させた。遊離ω3脂肪酸塩の場合、当該製品を完全に溶解させるために20μlの蒸留水を加えた。
バチルス・メガテリウムDSM 32963の場合、SPM生成酵素の細胞内的に関連する活性を実証することができた。0.1%グルコース(LBG)を伴う10mlのLuria Bertami培養液(LB、Thermo Fisher Scientific)から、100mLのフラスコにおいて30℃および200rpmで24時間かけて、バチルス・メガテリウムDSM 32963の培養を増殖させた。完了した培養を、LBGにおける200mlの本培養に移した。主培養を、2lのフラスコにおいて30℃および200rpmで6時間かけて増殖させた。次いで、当該細胞培養物を10ml収穫し、遠心分離処理(15min、4000rpm、室温)によって上清を除去し、細胞ペレットを、それぞれ、10mlのLBGおよび2mlの栄養補助剤(表2)に再懸濁させた。これらの培養物を、100mlの振とうフラスコにおいて、30℃および200rpmで16時間かけてインキュベートした。
細胞外に出現する18-HEPEの量を調査するため、バチルス・メガテリウムDSM 32963細胞を実施例1で説明されるように培養した。当該細胞を、10mlのLBGまたは、胆汁界面活性物質をシミュレートするために設計された、タウロコール酸塩、リン脂質、および他の成分の混合物である、9.76g/lのFeSSIF-V2(biorelevant.com)を含有するLBGに再懸濁させ、それぞれ、2mlの上清(表2)を加えた。さらに、振とうフラスコにおいて、細胞を伴わない様々な培地にも、それぞれ栄養補助剤を加え、同じ条件下において処理した(コントロール)。30℃および200rpmでの16時間のインキュベーションの後、当該培養上清およびコントロールにおける18-HEPE濃度を測定した(表4)。バチルス・メガテリウムDSM 32963細胞はω3リジン塩(AvailOm(登録商標))分散液から18-HEPEを合成することができることが示され、それは、細胞外において検出可能である。注目すべきことに、この方法によって検出されたω3→18-HEPEの変換率は、最高で0.075までであり、それは、国際公開第2017/041094号によって開示されている、エステル化された魚油における0.0005%の18-HEPEの元の含有量を超えるものである。より重要なことに、本発明者らは、バチルス・メガテリウム株によって、ω3リジン塩が、18-HEPEよりもさらに高い濃度において(例6参照)、生理的関連性のある多数の(最終)SPM生成物へと変換されることを発見した。
異なるバチルス種の、細胞内において18-HEPEを産生する能力を調査するため、異なる種の細胞を、実施例1に説明されるように培養した。当該細胞を、胆汁界面活性剤をシミュレートするために設計された、タウロコール酸塩、リン脂質、および他の成分の混合物である、9.76g/lのFeSSIF-V2(biorelevant.com)を含有する10mlのLGBに再懸濁させ、DOPCを伴う1.2mlのω3リジン塩分散液を加えた。30℃および200rpmで16時間のインキュベーション後の当該細胞における内部18-HEPE濃度を、実施例3で説明されるように測定した。
脂質メタボロミクス(Lipidometabolomics):
細菌性上清試料を、RP相固相抽出法を使用して脂質抽出を行い、その後、公開されている手順に従って、超高速液体クロマトグラフィESIタンデム質量分析法(UPLC-MS/MS)によって分析した[48]。これらの条件下において、およそ40の異なるLM、例えば、5-ヒドロキシ-エイコサペンタエン酸(5-HEPE)、8-HEPE、11-HEPE、12-HEPE、15-HEPE、18-HEPE、5-ヒドロキシ-エイコサテトラエン酸(5-HETE)、8-HETE、11-HETE、12-HETE、15-HETE、4-ヒドロキシ-DHA(4-HDHA)、7-HDHA、13-HDHA、14-HDHA、17-HDHA、リポキシンA4(LXA4)、LXB4、レゾルビンE1(RvE1)、RvE3、レゾルビンD1-5(RvD1-5)、AT-RvD1、RvD2、プロテクチンD1(PD1)、AT-PD1、マレシン1(MaR1)、MaR2、および4種の脂肪酸基質など、を、1pgのより低い検出限界によって検出することができる。
SPM産生能力について、それがバチルス・メガテリウム種の一般的現象であるか否かを特定するために、ならびに産生されるSPMのタイプおよび量において株に特異的な相違点を検出するために、様々な生息地から得られた47種のバチルス・メガテリウム株をスクリーニングした。ω3脂肪酸源としての役割を果たすAvailOm(登録商標)の分散液配合物を用いて、実施例4で詳述したように細胞を培養した。同時に、AvailOm(登録商標)の無細胞調製物を処理および分析し、酸素化生成物の非酵素的な自然発生的形成のためのコントロールとして役立てた。試験した全ての菌株は、測定可能な量(>1pg/ml)の様々なSPMおよびその前駆体を産生すること、これらの量が菌株の間で著しく異なること(最大で2.000倍まで)、ならびにほとんどの菌株においてRvE3の濃度が特に高いこと(最高で1.3μg/mlまで)が観察された。
以下の成分をHPMCカプセル(サイズ00)に充填した。
1. Balk EM, Lichtenstein AH: Omega-3 Fatty Acids and Cardiovascular Disease: Summary of the 2016 Agency of Healthcare Research and Quality Evidence Review. Nutrients 2017, 9(8).
2. Calder PC: Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta 2015, 1851(4):469-484.
3. Papanikolaou Y, Brooks J, Reider C, Fulgoni VL, 3rd: U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003-2008. Nutr J 2014, 13:31.
4. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL: Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Report 2015(79):1-16.
5. Schunck WH, Konkel A, Fischer R, Weylandt KH: Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases. Pharmacol Ther 2018, 183:177-204.
6. Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N: Novel anti-inflammatory--pro-resolving mediators and their receptors. Curr Top Med Chem 2011, 11(6):629-647.
7. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL, Merched A, Petasis NA et al: Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003, 171(12):6856-6865.
8. Prescott D, McKay DM: Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol 2011, 301(3):G487-497.
9. Rajasagi NK, Reddy PB, Mulik S, Gjorstrup P, Rouse BT: Neuroprotectin D1 reduces the severity of herpes simplex virus-induced corneal immunopathology. Invest Ophthalmol Vis Sci 2013, 54(9):6269-6279.
10. Baillie JK, Digard P: Influenza--time to target the host? N Engl J Med 2013, 369(2):191-193.
11. Morita M, Kuba K, Ichikawa A, Nakayama M, Katahira J, Iwamoto R, Watanebe T, Sakabe S, Daidoji T, Nakamura S et al: The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 2013, 153(1):112-125.
12. Zhu M, Wang X, Sun L, Schultzberg M, Hjorth E: Can inflammation be resolved in Alzheimer’s disease? Ther Adv Neurol Disord 2018, 11:1756286418791107.
13. Kasikara C, Doran AC, Cai B, Tabas I: The role of non-resolving inflammation in atherosclerosis. J Clin Invest 2018, 128(7):2713-2723.
14. Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, Titos E, Martinez-Clemente M, Lopez-Parra M, Arroyo V et al: Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009, 23(6):1946-1957.
15. Jin Y, Arita M, Zhang Q, Saban DR, Chauhan SK, Chiang N, Serhan CN, Dana R: Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci 2009, 50(10):4743-4752.
16. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D et al: Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007, 13(7):868-873.
17. Livne-Bar I, Wei J, Liu HH, Alqawlaq S, Won GJ, Tuccitto A, Gronert K, Flanagan JG, Sivak JM: Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury. J Clin Invest 2017, 127(12):4403-4414.
18. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN: Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005, 102(21):7671-7676.
19. Barnig C, Frossard N, Levy BD: Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther 2018, 186:98-113.
20. Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, Shimizu Y, Okajima F, Dobashi K, Mori M: Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 2008, 367(2):509-515.
21. Perretti M, Norling LV: Actions of SPM in regulating host responses in arthritis. Mol Aspects Med 2017, 58:57-64.
22. Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, Petasis NA, Serhan CN: The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J 2013, 27(7):2573-2583.
23. Liu Y, Fang X, Zhang X, Huang J, He J, Peng L, Ye C, Wang Y, Xue F, Ai D et al: Metabolic profiling of murine plasma reveals eicosapentaenoic acid metabolites protecting against endothelial activation and atherosclerosis. Br J Pharmacol 2018, 175(8):1190-1204.
24. Endo J, Sano M, Isobe Y, Fukuda K, Kang JX, Arai H, Arita M: 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J Exp Med 2014, 211(8):1673-1687.
25. Pochard C, Coquenlorge S, Jaulin J, Cenac N, Vergnolle N, Meurette G, Freyssinet M, Neunlist M, Rolli-Derkinderen M: Defects in 15-HETE Production and Control of Epithelial Permeability by Human Enteric Glial Cells From Patients With Crohn’s Disease. Gastroenterology 2016, 150(1):168-180.
26. Tang Y, Zhang MJ, Hellmann J, Kosuri M, Bhatnagar A, Spite M: Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 2013, 62(2):618-627.
27. Barden AE, Mas E, Croft KD, Phillips M, Mori TA: Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin. Am J Clin Nutr 2015, 102(6):1357-1364.
28. Miyata J, Arita M: Role of omega-3 fatty acids and their metabolites in asthma and allergic diseases. Allergol Int 2015, 64(1):27-34.
29. Mangino MJ, Brounts L, Harms B, Heise C: Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat 2006, 79(1-2):84-92.
30. Wang CW, Colas RA, Dalli J, Arnardottir HH, Nguyen D, Hasturk H, Chiang N, Van Dyke TE, Serhan CN: Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes. Infect Immun 2015, 84(3):658-665.
31. Ringholz FC, Buchanan PJ, Clarke DT, Millar RG, McDermott M, Linnane B, Harvey BJ, McNally P, Urbach V: Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis. Eur Respir J 2014, 44(2):394-404.
32. Robertson RC, Seira Oriach C, Murphy K, Moloney GM, Cryan JF, Dinan TG, Paul Ross R, Stanton C: Omega-3 polyunsaturated fatty acids critically regulate behaviour and gut microbiota development in adolescence and adulthood. Brain Behav Immun 2017, 59:21-37.
33. Mujico JR, Baccan GC, Gheorghe A, Diaz LE, Marcos A: Changes in gut microbiota due to supplemented fatty acids in diet-induced obese mice. Br J Nutr 2013, 110(4):711-720.
34. Vance RE, Hong S, Gronert K, Serhan CN, Mekalanos JJ: The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci U S A 2004, 101(7):2135-2139.
35. Furuya T, Shibata D, Kino K: Phylogenetic analysis of Bacillus P450 monooxygenases and evaluation of their activity towards steroids. Steroids 2009, 74(12):906-912.
36. Bernhardt R: Cytochromes P450 as versatile biocatalysts. J Biotechnol 2006, 124(1):128-145.
37. Capdevila JH, Wei S, Helvig C, Falck JR, Belosludtsev Y, Truan G, Graham-Lorence SE, Peterson JA: The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3. J Biol Chem 1996, 271(37):22663-22671.
38. Levitt MD: Volume and composition of human intestinal gas determined by means of an intestinal washout technic. N Engl J Med 1971, 284(25):1394-1398.
39. Albenberg L, Esipova TV, Judge CP, Bittinger K, Chen J, Laughlin A, Grunberg S, Baldassano RN, Lewis JD, Li H et al: Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 2014, 147(5):1055-1063 e1058.
40. Polus A, Zapala B, Razny U, Gielicz A, Kiec-Wilk B, Malczewska-Malec M, Sanak M, Childs CE, Calder PC, Dembinska-Kiec A: Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochim Biophys Acta 2016, 1861(11):1746-1755.
41. See VHL, Mas E, Prescott SL, Beilin LJ, Burrows S, Barden AE, Huang RC, Mori TA: Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial. Br J Nutr 2017, 118(11):971-980.
42. Weiss GA, Troxler H, Klinke G, Rogler D, Braegger C, Hersberger M: High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis 2013, 12:89.
43. Piewngam P, Zheng Y, Nguyen TH, Dickey SW, Joo HS, Villaruz AE, Glose KA, Fisher EL, Hunt RL, Li B et al: Pathogen elimination by probiotic Bacillus via signalling interference. Nature 2018, 562(7728):532-537.
44. Al-Thubiani ASA, Maher YA, Fathi A, Abourehab MAS, Alarjah M, Khan MSA, Al-Ghamdi SB: Identification and characterization of a novel antimicrobial peptide compound produced by Bacillus megaterium strain isolated from oral microflora. Saudi Pharm J 2018, 26(8):1089-1097.
45. Miura M, Ito K, Hayashi M, Nakajima M, Tanaka T, Ogura S: The Effect of 5-Aminolevulinic Acid on Cytochrome P450-Mediated Prodrug Activation. PLoS One 2015, 10(7):e0131793.
46. Ruettinger RT, Wen LP, Fulco AJ: Coding nucleotide, 5’ regulatory, and deduced amino acid sequences of P-450BM-3, a single peptide cytochrome P-450:NADPH-P-450 reductase from Bacillus megaterium. J Biol Chem 1989, 264(19):10987-10995.
47. Kang JY, Kim SY, Kim D, Kim DH, Shin SM, Park SH, Kim KH, Jung HC, Pan JG, Joung YH et al: Characterization of diverse natural variants of CYP102A1 found within a species of Bacillus megaterium. AMB Express 2011, 1(1):1.
48. Werz O, Gerstmeier J, Libreros S, De la Rosa X, Werner M, Norris PC, Chiang N, Serhan CN: Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun 2018, 9(1):59.
Claims (12)
- -バチルス・メガテリウム(Bacillus megaterium)属に属する少なくとも1種のプロバイオティク株と、
-エイコサペンタエン酸(EPA)、ドコサヘキサエン酸(DHA)、アラキドン酸(ARA)、α-リノレン酸、ステアリドン酸、エイコサテトラエン酸、ドコサペンタエン酸、リノール酸、γ-リノレン酸、から選択される少なくとも1種のω3またはω6脂肪酸を含む多価不飽和脂肪酸成分と、
を含む調製物であって、
前記多価不飽和脂肪酸成分が、ω3またはω6脂肪酸塩を含む、前記ω3またはω6脂肪酸塩は、リジン塩であり、
前記プロバイオティク株が、以下:バチルス・メガテリウムDSM 32963、バチルス・メガテリウムDSM 33296、またはバチルス・メガテリウムDSM 33299のうちの1つまたは複数から選択される、
調製物。 - 前記プロバイオティク株が、休眠形態において、または栄養細胞として存在する、請求項1に記載の調製物。
- 前記ω3またはω6脂肪酸が、遊離脂肪酸、塩、天然トリグリセリド、魚油、リン脂質エステル、またはエチルエステルのいずれかの形態である、請求項1に記載の調製物。
- 前記脂肪酸が、ω3脂肪酸EPAおよびDHAから選択されるか、または前記ω6脂肪酸成分がARAである、請求項1~3のいずれか一項に記載の調製物。
- さらに、5-アミノレブリン酸を含む、請求項1~4のいずれか一項に記載の調製物。
- 前記多価不飽和脂肪酸成分が、少なくとも1種のリン脂質と、少なくとも1種のω3またはω6脂肪酸とによる分散液を含む調製物を含む、請求項1~5のいずれか一項に記載の調製物。
- 遅延放出あるいは腸溶性放出または結腸放出のためのコーティングを含む、請求項1~6のいずれか一項に記載の調製物。
- 飼料用または食品用栄養補助剤としての、請求項1~7のいずれか一項に記載の調製物の使用。
- 医薬製品の製造のための、請求項1~7のいずれか一項に記載の調製物の使用。
- 請求項1~7のいずれか一項に記載の調製物と、
タンパク質、炭水化物、脂肪、さらなるプロバイオティクス、プレバイオティクス、酵素、ビタミン、免疫変調成分、ミルク代用品、ミネラル、アミノ酸、抗コクシジウム剤、酸系製品、医薬品、およびそれらの組合せから選択される、少なくとも1種の飼料原料または食品原料と、
を含有する飼料組成物または食料品組成物。 - 動物もしくは人間の、健康状態、腸の健康、心臓血管の健康、心血管代謝の健康、肺の健康、関節の健康、眼の健康、精神の健康、口腔衛生、または免疫の健康を改善するための、請求項10に記載の組成物。
- SPMの生物工学的生産のための、以下の特徴:
a)配列番号1または配列番号2,配列番号13または配列番号14,配列番号25または配列番号26によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有する16S rDNA配列、および/または
b)配列番号3,配列番号15,または配列番号27によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するyqfD配列、および/または
c)配列番号4,配列番号16,配列番号28によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgyrB配列、および/または
d)配列番号5,配列番号17,配列番号29によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するrpoB配列、および/または
e)配列番号6,配列番号18,配列番号30によるポリヌクレオチド配列に対して少なくとも99.5%、とりわけ100%の配列同一性を有するgroEL配列
を示す、休眠形態の、または栄養細胞としての、バチルス・メガテリウム株の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18209509 | 2018-11-30 | ||
EP18209509.1 | 2018-11-30 | ||
PCT/EP2019/082924 WO2020109474A1 (en) | 2018-11-30 | 2019-11-28 | Preparation comprising a probiotic strain of the genus bacillus megaterium and a polyunsaturated fatty acid component |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513633A JP2022513633A (ja) | 2022-02-09 |
JP7383023B2 true JP7383023B2 (ja) | 2023-11-17 |
Family
ID=64745858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021529679A Active JP7383023B2 (ja) | 2018-11-30 | 2019-11-28 | プロバイオティクス菌株と多価不飽和脂肪酸成分とを含む調製物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210392935A1 (ja) |
EP (1) | EP3886613A1 (ja) |
JP (1) | JP7383023B2 (ja) |
KR (1) | KR20210099037A (ja) |
CN (1) | CN113395908B (ja) |
AU (1) | AU2019387329A1 (ja) |
BR (1) | BR112021010335A2 (ja) |
CA (1) | CA3121033C (ja) |
MX (1) | MX2021006084A (ja) |
WO (1) | WO2020109474A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022051613A1 (en) * | 2020-09-04 | 2022-03-10 | Dsm Ip Assets B.V. | Production of hydroxylated polyunsaturated fatty acids |
AR128521A1 (es) * | 2022-02-21 | 2024-05-15 | Bioconsortia Inc | Microbios, composiciones microbianas y consorcios beneficiosos para la agricultura |
WO2024068304A1 (en) | 2022-09-30 | 2024-04-04 | Evonik Operations Gmbh | Probiotic strains for the treatment of irritable bowel syndrome and fodmap intolerance |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08298982A (ja) * | 1995-05-02 | 1996-11-19 | Aasu Giken:Kk | 複合微生物製剤 |
US6107334A (en) * | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
ATE344226T1 (de) * | 2000-02-16 | 2006-11-15 | Brigham & Womens Hospital | Aspirin-ausgelöste lipidmediatoren |
US20020188024A1 (en) * | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
DK3236782T3 (da) | 2014-12-23 | 2020-04-27 | Evonik Operations Gmbh | Fremgangsmåde til forøgelse af stabiliteten af en sammensætning, der omfatter flerumættede omega-3-fedtsyrer |
WO2016113400A1 (en) * | 2015-01-15 | 2016-07-21 | JeNaCell GmbH | Multi-phase bacterially-synthesized-nanocellulose biomaterials and method for producing the same |
US10653703B2 (en) | 2015-09-03 | 2020-05-19 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same |
EP3248467A1 (de) | 2016-05-25 | 2017-11-29 | Evonik Technochemie GmbH | Verfahren zur herstellung einer zusammensetzung enthaltend omega-3-fettsäure-l-lysin-salze |
AU2017319484B2 (en) * | 2016-08-30 | 2022-04-07 | Amvac Chemical Corporation | Defined microbial compositions |
-
2019
- 2019-11-28 MX MX2021006084A patent/MX2021006084A/es unknown
- 2019-11-28 KR KR1020217019791A patent/KR20210099037A/ko unknown
- 2019-11-28 JP JP2021529679A patent/JP7383023B2/ja active Active
- 2019-11-28 CA CA3121033A patent/CA3121033C/en active Active
- 2019-11-28 CN CN201980078589.8A patent/CN113395908B/zh active Active
- 2019-11-28 EP EP19832564.9A patent/EP3886613A1/en active Pending
- 2019-11-28 WO PCT/EP2019/082924 patent/WO2020109474A1/en unknown
- 2019-11-28 US US17/296,465 patent/US20210392935A1/en active Pending
- 2019-11-28 BR BR112021010335A patent/BR112021010335A2/pt unknown
- 2019-11-28 AU AU2019387329A patent/AU2019387329A1/en active Pending
Non-Patent Citations (4)
Title |
---|
Appl Microbiol Biotechnol, 2005, Vol.69, p.463-468 |
Asia Pac J Clin Nutr, 2008, Vol.17(S1), p.192-195 |
PLoS ONE, 2015, Vol.10, No.7, e0131793 |
油化学,1982,第31巻,第6号,p.19-22 |
Also Published As
Publication number | Publication date |
---|---|
CN113395908A (zh) | 2021-09-14 |
MX2021006084A (es) | 2021-07-06 |
AU2019387329A1 (en) | 2021-07-15 |
CN113395908B (zh) | 2024-06-11 |
US20210392935A1 (en) | 2021-12-23 |
CA3121033C (en) | 2023-06-13 |
WO2020109474A1 (en) | 2020-06-04 |
CA3121033A1 (en) | 2020-06-04 |
JP2022513633A (ja) | 2022-02-09 |
BR112021010335A2 (pt) | 2021-11-16 |
EP3886613A1 (en) | 2021-10-06 |
KR20210099037A (ko) | 2021-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210163878A1 (en) | Modulation of tissue fatty acid composition of a host by human gut bacteria | |
JP7383023B2 (ja) | プロバイオティクス菌株と多価不飽和脂肪酸成分とを含む調製物 | |
AU2016203427B2 (en) | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof | |
US20220265749A1 (en) | Preparation comprising omega-3 fatty acid salts and extracts of gum resins from boswellia species | |
JP4565750B2 (ja) | 共役リノール酸エステルの製造法 | |
Ma et al. | Targeting gut microbiota and metabolism as the major probiotic mechanism-An evidence-based review | |
TW201036554A (en) | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof | |
JP2009520470A (ja) | 新規の乳酸桿菌株及びその使用 | |
JP2022509814A (ja) | リン脂質と脂肪酸塩の分散体を含む調製物 | |
EP3886832A1 (en) | Preparation for use to increase the formation of one or more specialized pro-resolving lipid mediators (spm) | |
US20240180978A1 (en) | Preparations comprising probiotic strains and l-tryptophan | |
KR20140108281A (ko) | 건강 유지 및 급성 및 만성 장애의 치료를 위한 지질 보조제를 함유하는 츄어블 웨이퍼 | |
CN118252869A (en) | Formulation comprising omega-3 fatty acid salts and gum resin extract from boswellia species | |
Sukrutha et al. | Omega-3 fatty acids: A review of its wide range of applications and possible mechanisms of action | |
WO2024105265A1 (fr) | Limosilactobacillus mucosae et désordres nécessitant un accroissement du niveau de glp-1 | |
IES20080790A2 (en) | Modulation of tissue fatty acid composition of a host by human gut bacteria | |
IE20080790U1 (en) | Modulation of tissue fatty acid composition of a host by human gut bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210803 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230821 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231031 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231107 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7383023 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |